0001209191-20-020507.txt : 20200320 0001209191-20-020507.hdr.sgml : 20200320 20200320174906 ACCESSION NUMBER: 0001209191-20-020507 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200318 FILED AS OF DATE: 20200320 DATE AS OF CHANGE: 20200320 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hoerter Steven L. CENTRAL INDEX KEY: 0001533451 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38219 FILM NUMBER: 20733077 MAIL ADDRESS: STREET 1: 2525 28TH STREET, SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001654151 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200299725 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-209-6400 MAIL ADDRESS: STREET 1: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC DATE OF NAME CHANGE: 20150928 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-03-18 0 0001654151 Deciphera Pharmaceuticals, Inc. DCPH 0001533451 Hoerter Steven L. C/O DECIPHERA PHARMACEUTICALS, INC. 200 SMITH STREET WALTHAM MA 02451 1 1 0 0 President and CEO Common Stock 2020-03-18 4 M 0 2250 25.40 A 54250 D Common Stock 2020-03-19 4 F 0 4494 35.78 D 49756 D Common Stock 2020-03-19 4 F 0 1012 36.88 D 48744 D Common Stock 2020-03-19 4 F 0 4230 38.26 D 44514 D Common Stock 2020-03-19 4 F 0 2164 39.22 D 42350 D Common Stock 2020-03-19 4 F 0 520 39.98 D 41830 D Stock Option (Right to Buy) 25.40 2019-03-18 4 A 0 2250 0.00 D 2029-03-17 Common Stock 2250 397750 D On March 18, 2019 the Reporting Person was granted 22,000 Restricted Stock Units (RSUs) which vested in full on March 18, 2020 and was granted 30,000 RSUs which vest in four (4) equal annual installments beginning on March 18, 2020. These RSUs were reported in Table I on a Form 4 filed on March 20, 2019. The sale of shares reported in this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax obligations. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.27 to $36.01, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.73 to $37.24, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.77 to $38.76, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.79 to $39.77, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.88 to $40.01, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. 25% of the options shall vest on March 18, 2020, and the remaining options shall vest in equal monthly installments over the following three years, subject to continued service through such dates. /s/ Jeffrey Held, Attorney-in-Fact 2020-03-20